Gastric cancer is one of the leading causes of cancer deaths globally. Advanced gastric cancer and esophago-gastric junction cancer have a poor prognosis even after curative surgery and adequate lymph node dissection.

Some treatments have been studied and applied to improve survival rates. Neoadjuvant chemotherapy or perioperative chemotherapy have been used to convert unresectable tumours into resectable tumours and to increase microscopic complete tumour resection rates. Neoadjuvant or perioperative chemotherapy could potentially increase the curative resection rate, improve the tumour downstaging possibilities, and reduce the tumour-related symptoms if the chosen drugs have an effect on the specific tumour biology. However, perioperative chemotherapy might potentially increase surgical-related complications and as a consequence increase perioperative mortality.

This Special Issue aims to evaluate the effects of neoadjuvant or perioperative therapy on gastric cancer and esophago-gastric junction cancer. Original research and review articles are welcome.

Potential topics include but are not limited to the following:

• Potential prognostic or predictive biomarkers for advanced gastric cancer or esophago-gastric junction cancer for neoadjuvant or perioperative therapy
• Tumour microenvironment: molecular mechanisms and signalling pathways in therapeutic strategies of neoadjuvant therapy
• Neoadjuvant therapy versus neoadjuvant chemoradiotherapy for locally advanced gastric cancer
• Impact on surgery and short-term outcome after neoadjuvant therapy
• Oncologic outcome after neoadjuvant therapy
• The role of adjuvant chemotherapy after radical resection of locally advanced gastric cancer following neoadjuvant therapy